A study explored the role of HORMAD1 gene activity in triple negative breast cancer and tested targeted inhibitors. Early experiments reduced tumor growth, highlighting potential therapeutic ...
Hearing the words “triple-negative breast cancer” (TNBC) can be overwhelming. It’s a diagnosis that sounds heavy — not just because breast cancer itself is frightening, but because this particular ...
Triple-negative breast cancer lacks key receptors, requiring chemotherapy, immunotherapy, surgery, and radiation, with treatment tailored to cancer stage. Early-stage TNBC treatment often involves ...
Pathological complete response at surgery was higher with INT230-6 pre-treatment plus Keynote-522 (5/7; 71.4%) than with Keynote-522 alone (2/6; 33%), with one evaluation pending. Grade ≥3 adverse ...
Scientists at Oregon Health & Science University have developed a new molecule that could open the door to treating triple-negative breast cancer, one of the most aggressive and difficult-to-treat ...
Enhancing care of patients with HR+/HER2- early breast cancer at high risk of recurrence through an expansive curriculum: Real world outcomes (RWO) from a 6 month analysis.
Triple-negative breast cancer is particularly aggressive and difficult to treat; but recent research may offer a new way to target the often-deadly disease. A team of researchers from the University ...
About 50% of triple-negative breast cancer (TNBC) patients develop resistance to therapy. When resistance arises, tumors are more likely to come back ...
In almost all solid tumors - i.e. cancers with a solid tissue structure - the detection of tumor cells in the lymph nodes is considered a decisive marker for the progression of the disease. Lymph node ...
This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting I. This abstract does not include a full text component.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results